Thelansis’s “Axial Spondyloarthritis (axSpA) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Axial spondyloarthritis is a chronic immune-mediated inflammatory rheumatic disease affecting the sacroiliac joints and spine, causing inflammatory back pain, stiffness, impaired function, and, in some patients, progressive structural damage and spinal ankylosis. The treatment landscape has evolved from NSAIDs and other anti-inflammatory measures to targeted therapies, with TNF and IL-17 inhibitors established as major biologic options and JAK inhibitors expanding the oral treatment landscape. Despite these advances, substantial unmet needs remain, including delayed diagnosis, incomplete responses, treatment intolerance, and uncertainty over whether current therapies can reliably prevent new bone formation and long-term structural progression. This has driven development toward increasingly selective mechanisms. Bimekizumab, which simultaneously inhibits IL-17A and IL-17F, is already approved for both non-radiographic axSpA and ankylosing spondylitis, while emerging approaches such as selective ERAP1 inhibition are exploring entirely new biology. For stakeholders, axSpA represents an important therapeutic frontier where the next advance will depend not only on controlling inflammation, but on achieving durable disease control and more meaningful protection against structural progression.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Axial Spondyloarthritis (axSpA) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Axial Spondyloarthritis (axSpA) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.